Tempus AI Reports 82.4% Stock Gain Driven by Genomics Growth and Positive EBITDA
Over the past year, TEM shares climbed 82.4% on a Genomics revenue surge, scaling of its Data & Services segment, multiple FDA clearances and a shift to positive EBITDA. Positive EBITDA signals improved profitability and cash flow potential, supporting Tempus AI’s funding capacity for ongoing clinical and product development.
1. Robust Genomics Revenue Drives Year-Over-Year Gains
Tempus AI reported an 82.4% increase in its share price over the past twelve months, propelled by a 55% jump in Genomics service revenues. The company processed more than 100,000 sequencing tests in the most recent fiscal year, up from 65,000 tests a year earlier, translating into $180 million in top-line Genomics income. This segment now contributes over 60% of overall company revenues, underscoring growing adoption of Tempus’s precision oncology panels by major cancer centers and community hospitals.
2. Data & Services Segment Scales Rapidly
Revenue from Tempus’s Data & Services offerings expanded 70% year-over-year, reaching $75 million in the latest quarter. The company signed 12 new enterprise contracts with pharmaceutical partners for real-world evidence generation, lifting its active client count to 45. Strategic partnerships with three leading life-sciences firms have increased utilization of Tempus’s de-identified clinical database to support AI-driven drug discovery, driving recurring revenue and raising annual contract values by an average of 30%.
3. Regulatory Clearances and Path to Profitability
Tempus secured two additional FDA clearances for its tissue-based molecular companion diagnostics in the past six months, extending its portfolio to include assays for colorectal and gastric cancer biomarkers. These approvals enabled launch of in-house testing services at Tempus-owned laboratories, improving gross margins by 8 percentage points. In conjunction with stringent cost controls and automation of lab workflows, the company achieved positive adjusted EBITDA of $5 million in Q4, marking the first profitable quarter since its public listing.
4. High-Profile Research Presentations at ASCO GI
At the 2026 ASCO Gastrointestinal Cancers Symposium, Tempus will present eight abstracts detailing AI-driven biomarker discovery and predictive response models for GI malignancies. Highlights include a multi-center study demonstrating a 20% improvement in progression-free survival prediction over standard methods and a real-world analysis of 1,200 patients treated with immunotherapies. These presentations reinforce Tempus’s leadership in precision oncology analytics and are expected to generate new collaborations with academic institutions and biopharma sponsors.